Table 3.

Cancer-Specific Survival.

		Kaplan-Meier			Cox UVA			Cox MVA
		CSS2 (%)	95%CI (%)	p	HR	95%CI	p (class)	HR	95%CI	p (class)	p (variable)
Diabetes/Metformin Category	D + M	88.8	79.2–94.1	< 0.01	.	.	.	.	.	.	< 0.01
	nD	73.7	70.3–76.8	.	2.54	1.30–4.95	0.01	2.33	1.16–4.65	0.02	.
	DnM	66.1	59.6–71.8	.	3.50	1.76–6.97	< 0.01	3.03	1.49–6.16	< 0.01	.
Age	66–69	77.6	71.9–82.2	< 0.01	.	.	.	.	.	.	< 0.01
	70–74	78.0	72.8–82.3	.	0.99	0.70–1.40	0.95	1.04	0.73–1.50	0.82	.
	75+	67.7	63.2–71.7	.	1.56	1.16–2.10	< 0.01	1.77	1.29–2.44	< 0.01	.
Sex	Male	76.6	72.9–79.9	0.01	.	.	.	.	.	.	< 0.01
	Female	68.6	64.0–72.7	.	1.38	1.09–1.74	0.01	1.55	1.19–2.02	< 0.01	.
Race/Ethnicity	White Non-Hispanic	74.8	71.7–77.7	0.04	.	.	.	.	.	.	0.77
	Non-White or Hispanic	66.1	59.0–72.4	.	1.33	1.01–1.74	0.04	1.05	0.77–1.42	0.77	.
Marital Status	Married	79.8	75.8–83.1	< 0.01	.	.	.	.	.	.	0.12
	Non-Married	67.5	63.3–71.3	.	1.70	1.33–2.17	< 0.01	1.24	0.95–1.63	0.12	.
Geographic Region	West	70.7	66.2–74.7	0.08	.	.	.	.	.	.	0.12
	East	75.6	68.6–81.3	.	0.81	0.58–1.14	0.22	0.68	0.46–1.02	0.06	.
	Midwest	82.6	74.6–88.2	.	0.60	0.38–0.94	0.02	0.60	0.36–1.00	0.05	.
	South	71.4	65.7–76.4	.	1.02	0.77–1.34	0.92	0.77	0.55–1.08	0.12	.
Population Density	Metropolitan	73.5	70.3–76.4	0.41	.	.	.	.	.	.	0.78
	Non-Metropolitan	71.7	65.1–77.2	.	1.12	0.85–1.49	0.42	0.95	0.68–1.34	0.78	.
Year of Diagnosis	2008	73.8	68.9–78.1	0.87	.	.	.	.	.	.	0.90
	2009	72.3	67.4–76.5	.	1.07	0.81–1.42	0.61	1.06	0.80–1.42	0.68	.
	2010	73.8	67.5–79.1	.	1.02	0.76–1.37	0.92	1.06	0.78–1.44	0.70	.
Primary Site	Oral Cavity	77.0	73.1–80.4	< 0.01	.	.	.	.	.	.	0.01
	Oropharynx	70.5	65.4–75.0	.	1.40	1.08–1.82	0.01	0.62	0.45–0.85	< 0.01	.
	Other	65.5	57.2–72.5	.	1.68	1.22–2.32	< 0.01	0.71	0.49–1.02	0.06	.
T-Classification	T0–1	89.1	85.1–92.1	< 0.01	.	.	.	.	.	.	< 0.01
	T2	69.8	63.9–74.9	.	2.98	2.01–4.42	< 0.01	1.95	0.77–4.92	0.16	.
	T3–4	56.7	50.6–62.3	.	5.36	3.68–7.80	< 0.01	7.62	3.17–18.3	< 0.01	.
	Unknown	74.6	66.5–81.1	.	2.74	1.73–4.36	< 0.01	5.20	1.91–14.2	< 0.01	.
N-Classification	N0	80.9	77.5–83.9	< 0.01	.	.	.	.	.	.	< 0.01
	N1	63.7	55.8–70.6	.	2.14	1.57–2.91	< 0.01	1.63	1.15–2.31	0.01	.
	N2–3	62.6	56.6–68.0	.	2.21	1.69–2.88	< 0.01	1.80	1.30–2.49	< 0.01	.
Comorbidity Index	0	76.1	72.6–79.2	< 0.01	.	.	.	.	.	.	0.04
	1+	67.8	62.7–72.5	.	1.47	1.16–1.86	< 0.01	1.31	1.02–1.69	0.04	.
Tract % High School Only	≤ Median	76.0	75.0–79.6	0.01	.	.	.	.	.	.	< 0.01
	> Median	70.2	66.1–73.9	.	1.39	1.10–1.76	0.01	1.56	1.15–2.11	< 0.01	.
Tract % Below Poverty	≤ Median	78.6	74.7–81.9	< 0.01	.	.	.	.	.	.	0.24
	> Median	67.7	63.5–71.6	.	1.66	1.30–2.10	< 0.01	1.19	0.89–1.58	0.24	.
Teaching Hospital	No or Unknown	69.4	65.0–73.3	0.01	.	.	.	.	.	.	0.13
	Yes	76.3	72.5–79.7	.	0.72	0.57–0.91	0.01	0.82	0.64–1.06	0.13	.
Surgery	No	58.6	53.6–63.2	< 0.01	.	.	.	.	.	.	< 0.01
	Yes	83.0	79.8–85.8	.	0.34	0.26–0.43	< 0.01	0.42	0.30–0.58	< 0.01	.
Chemotherapy	No	80.4	76.8–83.4	< 0.01	.	.	.	.	.	.	0.74
	Yes	64.5	59.9–68.7	.	1.92	1.51–2.44	< 0.01	1.06	0.77–1.44	0.74	.
Radiotherapy	No	85.4	81.3–88.6	< 0.01	.	.	.	.	.	.	0.05
	Yes	66.3	62.5–69.8	.	2.50	1.86–3.36	< 0.01	0.53	0.28–1.01	0.05	.
ACEi or ARB	No	71.0	67.3–74.3	0.04	.	.	.	.	.	.	0.52
	Yes	77.0	72.3–81.0	.	0.77	0.60–0.99	0.04	0.91	0.69–1.21	0.52	.
Statin	No	69.2	65.5–72.6	< 0.01	.	.	.	.	.	.	0.09
	Yes	80.1	75.6–83.8	.	0.61	0.47–0.80	< 0.01	0.77	0.57–1.04	0.09	.
HTN/CKD	No	75.7	69.9–80.5	0.29	.	.	.	.	.	.	0.21
	Yes	72.3	68.9–75.3	.	1.16	0.88–1.54	0.29	1.23	0.89–1.71	0.21	.
HLD	No	69.1	63.9–73.7	0.03	.	.	.	.	.	.	0.21
	Yes	75.2	71.7–78.2	.	0.77	0.60–0.97	0.03	0.83	0.63–1.11	0.21	.

Abbreviations: CSS2, 2-year cancer-specific survival; 95%CI, 95% confidence interval; HR, hazard ratio; UVA, univariate analysis; MVA, multivariate analysis; nD, non-diabetic; DnM, diabetic not taking metformin; D + M diabetic taking metformin; NH, non-Hispanic; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotension II receptor blocker; HTN, hypertension; CKD, chronic kidney disease; HLD, hyperlipidemia.